IceCure Medical (ICCM) Q3 2026 earnings review

IceCure US sales surge, but cash dwindles and schedules slip

IceCure Medical, which makes liquid-nitrogen devices that freeze breast tumors without surgery, expanded its U.S. commercial reach while standalone third-quarter sales slipped. Nine-month U.S. sales jumped 83%, but subtracting first-half figures shows third-quarter total revenue fell 3% from a year ago to $824 thousand by our math. Gross margin dropped to 26% by our math, and higher clinical trial spending pushed quarterly operating cash burn to $4.4 million.

At a glance
U.S. sales (first nine months)+83% from a year ago, reaching 21 states
Third-quarter revenue (by our math)$824K -3.1% from a year ago and -9.2% from Q2
Ending cash and equivalents$8.2M down from $12.0M in June; ~1.9 quarters of burn
2027 revenue outlookNew qualitative call for double-digit growth

โš–๏ธ Verdict: ๐Ÿ”ด Bearish

The story got worse because cash burn accelerated while clinical and international schedules slipped again. Cash fell to $8.2 million, leaving under two quarters of funding by our math after share sales already more than doubled the share count this year. Chief executive Eyal Shamir also expressed doubt about meeting the three-year 400-patient FDA study timeline and pushed Terumo's Japan filing into the first half of 2027.

The question now is whether U.S. clinic expansion can generate enough recurring probe sales to narrow losses before repeated share offerings dilute current owners further. Either newly hired U.S. reps drive a fourth-quarter revenue rebound, or the cash shortfall forces another deeply discounted financing first. Full-year U.S. probe revenue and the next capital raise will settle it.

๐Ÿ‚ Bull Case

๐ŸŸข strengthening GROWTH

US Sales Almost Doubled Over Nine Months

IceCure Medical sells ProSense, a liquid-nitrogen device that freezes and destroys tumors without open surgery, along with single-use needle probes for each treatment. Chief executive Eyal Shamir said the first nine months of 2026 showed progress in "translating our regulatory and clinical achievements into commercial growth, particularly in the United States". Nine-month U.S. sales rose 83% from a year ago, lifting total nine-month revenue 26% to $2.6 million.

The Israeli medical device maker widened its U.S. commercial reach from 11 states a year ago to 21 states in the third quarter. Management hired sales specialists in Florida, Southern California, New York and the Midwest, plus clinical trainers. When asked for the U.S. installed base of machines, Shamir did not give the number, saying the firm will update the figure in a few weeks or months.

What to watch: full-year U.S. revenue for single-use probes in the annual report. Rising probe sales would prove that new clinics are treating patients regularly rather than just buying their first machine.

๐ŸŸข strengthening PRODUCT

Oncology Group Petitions For Cancer Guideline Inclusion

Wider doctor adoption depends on clinical guidelines and medical studies supporting tumor freezing over surgical removal. During the third quarter, the Society of Interventional Oncology, a medical group, petitioned the National Comprehensive Cancer Network to "include percutaneous cryoablation as a treatment option in its breast cancer guidelines". IceCure also highlighted two new peer-reviewed studies on early-stage breast cancer and lymph node tumors.

Inclusion in national cancer guidelines matters because U.S. hospitals and insurers rely on those standards when deciding which procedures to cover and perform. While a permanent U.S. doctor billing code is not targeted until 2028, guideline backing helps sales reps convince breast surgeons to adopt ProSense under existing hospital billing codes.

What to watch: the National Comprehensive Cancer Network's response to the petition and the American Medical Association's billing code panel summary. Favorable decisions from those bodies would lower the barrier for doctors to bill insurers.

๐Ÿป Bear Case

๐Ÿ”ด๐Ÿ”ด new GROWTH contradicts narrative

Third-Quarter Revenue And Gross Margin Shrank

IceCure published only nine-month figures in its release, highlighting 26% nine-month revenue growth and 22% gross profit growth. Subtracting the first-half results reveals a weaker third quarter underneath the cumulative numbers. By our math, third-quarter revenue fell 3.1% from a year ago and 9.2% from the second quarter to $824 thousand, as weaker international sales offset U.S. gains.

  • Third-quarter revenue: $824 thousand by our math, down from $850 thousand a year ago and $907 thousand in the second quarter
  • Third-quarter gross margin: 26.0% by our math, down 6.6 percentage points from 32.6% a year ago as cost of sales rose to 74.0% of revenue
  • Third-quarter research and development cost: $2.28 million by our math, up 69.2 percentage points of revenue from a year ago to 276.5% of sales
  • Third-quarter sales and marketing cost: $1.15 million by our math, up 32.0 percentage points of revenue from a year ago to 139.7% of sales

What to watch: fourth-quarter revenue against last year's record $1.28 million. A drop below last year's fourth quarter would show that U.S. clinic additions are not yet overcoming choppy overseas distributor orders.

๐Ÿ”ด๐Ÿ”ด persistent CAPITAL ALLOCATION

Cash Covers Under Two Quarters Of Spending

Finance chief Meir Peleg said the tumor-freezing specialist continues to carefully manage its financial resources while investing in U.S. sales and clinical studies. Nine-month operating cash outflow rose to $12.6 million from $9.6 million a year ago. Subtracting the first half shows that third-quarter operating cash outflow reached $4.4 million by our math, up from $2.7 million in the prior-year quarter.

Cash on hand dropped from $12.0 million in June to $8.2 million in September. At the third-quarter burn rate, $8.2 million covers 1.9 quarters of operations by our math. Funding the business through share sales has already lifted the issued share count 128.2% since December 2025 to 5.56 million shares, which shrank nine-month net loss per share 33.9% even as net loss widened.

What to watch: new share offering filings before year-end or in early 2027. With less than two quarters of cash left at the third-quarter pace, another capital raise would dilute existing shareholders further.

๐Ÿ”ด persistent PRODUCT

Post-Marketing Study And Japan Timelines Slipped Again

As part of its U.S. breast cancer clearance, the Food and Drug Administration required IceCure to run ChoICE, a post-marketing study of 400 patients across 30 clinics. Last quarter, Shamir aimed to enroll the first patient before September 1 and reach 80 patients by March 2027. IceCure treated its first patient in October and currently has four active sites, with two patients enrolled.

Asked about the deadlines, Shamir said, "I am not sure that we will be able to do the 400 within the three years, because some of the contracts, agreements, some of the sites is taking them longer time." Overseas timelines also moved out: partner Terumo's Japanese regulatory filing, previously targeted for the first half of 2026, is now expected "during the first semester of 2027".

What to watch: ChoICE patient enrollment by March 2027 against the 80-patient first-year goal. Continued contracting delays would slow the conversion of study hospitals into regular commercial buyers of single-use probes.

๐Ÿ”ด persistent DISCLOSURE

Risks this quarter didn't answer

Four standing risks from prior filings received no update in the third-quarter release or on the conference call.

  • Tel Aviv class-action lawsuit: mediation stay on the $134 million claim ran through November 10, 2026, eight days before the release, with no outcome disclosed.
  • Permanent U.S. doctor billing code: no update on the September 2026 American Medical Association panel meeting; full code still not expected before 2028.
  • Active U.S. machine count: management did not give the third-quarter installed base or per-site probe usage; next update promised in a few weeks or months.
  • Currency drag on margins: third-quarter gross margin fell to 26.0% by our math, with no breakdown of how much the Israeli shekel hurt costs.

๐Ÿ‘“ Other Themes

new GROWTH

China Approval And Netherlands Distributor Expand Reach

Outside the United States, IceCure received regulatory approval from China's National Medical Products Administration to sell ProSense as a Class III medical device and signed an exclusive distribution contract in the Netherlands. Shamir said the firm is discussing a distribution partnership in China and expects a Health Canada breast cancer approval "in the next few months", so neither market adds revenue yet.

๐Ÿ’ฒ Other KPIs

Trade receivables (26Q3) $391 thousand
โ‡˜ decelerating

Money owed by customers for delivered machines and probes rose 18.1% from $331 thousand at year-end 2025, but dipped from $413 thousand in June as third-quarter revenue slowed. Collections kept pace with sales, producing a $60 thousand cash outflow over nine months.

Inventory (26Q3) $2.58 million
โ‡’ stable

Stockpiled consoles and probes held near $2.6 million for a fourth straight quarter, down 1.8% from December 2025 and up 1.3% from June. At the third-quarter cost of sales pace, the medical device maker holds about four quarters of inventory on hand by our math.

Capital expenditures (26Q3) $154 thousand (9M)
โ‡— accelerating

Spending on property and equipment over nine months grew fivefold from $31 thousand a year ago, reaching 5.8% of nine-month revenue. By our math, the Israeli company spent $93 thousand in the third quarter alone, up from $51 thousand in the first quarter and $10 thousand in the second.

๐Ÿ”ฎ Guidance

Q4 2026 Revenue (qualitative) Above Q3 2026 ($824 thousand)
โ‡— accelerating

New. North America sales vice president Shad Good said "We would expect that our sales revenue would continue to increase quarter-over-quarter," and Peleg added that fourth-quarter revenue "it will be better, we assume, of course, and project it will be better than Q3 2026". Peleg noted that the fourth quarter is seasonally strongest, though he could not promise it will beat last year's $1.28 million record.

FY2027 Revenue (qualitative) Double-digit percentage growth
โ‡— accelerating

New. While declining to issue a numeric range, Peleg stated that "the projection for next year for revenue is a healthy double-digit growth" as U.S. sales reps in Florida, California, New York and the Midwest ramp up clinic adoption.

โ“ Key Questions

What happened when the class-action mediation stay ended?

The Tel Aviv District Court certified a class action seeking about $134 million over a 2021 share placement, and the mediation stay expired on November 10, 2026. That claim is more than 16 times current cash, yet management gave no update.

How many active US machines are installed today?

Management stopped reporting the exact number of active U.S. ProSense accounts after the first quarter's 19 accounts, and Shamir deferred the question on the call. Without the machine count and probe reorders per site, investors cannot separate one-time console sales from recurring procedure usage.

Did the September billing code panel accept breast cryoablation?

Last quarter Shamir said breast tumor freezing was on the September 2026 American Medical Association panel agenda for a permanent doctor billing code. Neither the release nor the call mentioned the outcome of that meeting.

How will IceCure fund operations past early 2027?

By our math, third-quarter operating cash burn of $4.4 million leaves 1.9 quarters of cash at $8.2 million. Investors need to know how much capacity remains on the May 2026 share-sale agreement and when the next financing will occur.